A Phase 3 interventional study of Benralizumab and Placebo in Bullous Pemphigoid, sponsored by AstraZeneca. Terminated at 39 sites in 11 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2024-11-29.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to investigate the use of benralizumab is effective in the treatment of patients symptomatic Bullous Pemphigoid (BP).
Bullous pemphigoid (BP) is a rare disease mainly affecting the elderly. BP is associated with significant morbidity and increased mortality secondary to increased risk of secondary infections, comorbid conditions, and serious side effects from high-dose steroids and immunosuppressants. The aim of this study is to investigate the use of benralizumab as a treatment for patients symptomatic with Bullous Pemphigoid (BP).
64 studies on the registry are indexed under Pemphigoid, Bullous; 8 are open to participants now.
This study's enrollment of 67 is above the median of 30 across 39 interventional studies indexed under Pemphigoid, Bullous.
Browse Pemphigoid, Bullous studies →AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants are eligible to be included in the study only if all of the following criteria apply:
/Age
Adult participants ≥ 18 years of age at the time of signing the ICF.
Type of Participant and Disease Characteristics
Participants must have clinical features of BP (eg, urticarial or eczematous or erythematous plaques, bullae, pruritus) at the screening visit and confirmed diagnosis with histology, direct immunofluorescence, and serology at randomization. Required for inclusion:
(i) indirect immunofluorescence (IgG on the roof of salt- split skin). (ii) positive serology on ELISA for BPAG1 (230-kd). (iii) positive serology on ELISA for BPAG2 (180-kd).
Sex 7 Male or female.
Reproduction 8 Female participants capable of having children must meet both of the following conditions ([a] and [b]):
(a) Have a negative urine pregnancy test at screening and (b) Must agree to use a highly effective method of (confirmed by the investigator) from randomization throughout the study duration and within 12 weeks after last dose of IP. Highly effective forms (those that can achieve a failure rate of less than 1% per year when used consistently and correctly) of birth control include: (i) Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation - oral, intravaginal, or transdermal.
(ii) Progestogen-only hormonal contraception associated with inhibition of ovulation - oral, injectable, or implantable.
(iii) Intrauterine device. (iv) Intrauterine hormone-releasing system. (v) Bilateral tubal occlusion. (vi) Sexual abstinence, ie, refraining from heterosexual intercourse (the reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the participant).
(vii) Vasectomized sexual partner provided that partner is the sole sexual partner of the female of (FOCBP) study participant and that the vasectomized partner has received medical assessment of the surgical success.
(c) Females not of childbearing potential are defined as females who are either permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are . Females will be considered postmenopausal if they have been amenorrhoeic for ≥ 12 months prior to the planned date of randomization without an alternative medical cause. The following age-specific requirements apply: (i) Females \< 50 years old will be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatment and follicle-stimulating hormone (FSH) levels in the postmenopausal range. Until FSH is documented to be within menopausal range, treat the participant as a female of childbearing potential.
(ii) Females ≥ 50 years old will be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatment.
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
Medical Conditions
Current or history of within 5 years before the screening visit with the following exceptions:
Current active liver disease.
A history of known immunodeficiency disorder including a positive (HIV) test.
Prior/Concomitant Therapy
Use of medication, including, but not limited to: methotrexate, cyclosporine, azathioprine, within 4 weeks or 5 half-lives prior to the date informed consent is obtained, whichever is longer.
Other Exclusions
For females only: Currently pregnant, breastfeeding, or lactating females.
(a) A urine pregnancy test must be performed for FOCBP at Visit 1. A positive urine test result must be confirmed with a serum pregnancy test. If serum test is positive, the participant should be excluded.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Benralizumab subcutaneously (SC) loading dose followed by repeat dosing of SC benralizumab plus Oral Corticosteroids per SoC tapering. Open-Label (OLE): after completion of the double-blind treatment period, all participants will have the option of entering an OLE period, starting at week 36 benralizumab SC until study closure.
Biological: Benralizumab
Placebo plus Oral Corticosteroids per SoC tapering. Open-Label (OLE): after completion of the double-blind treatment period, all participants will have the option of entering an OLE period, starting at week 36 benralizumab SC until study closure.
Biological: Placebo
Benralizumab subcutaneously (SC) loading dose followed by repeat dosing of SC benralizumab plus Oral Corticosteroids per SoC tapering. Open-Label (OLE): after completion of the double-blind treatment period, all participants will have the option of entering an OLE period, starting at week 36 benralizumab SC until study closure.
Also known as: Benralizumab, Benra, Fasenra
Placebo plus Oral Corticosteroids per SoC tapering. Open-Label (OLE): after completion of the double-blind treatment period, all participants will have the option of entering an OLE period, starting at week 36 benralizumab SC until study closure.
Percentage of Responders at Week 36
A responder was defined as a participant who was in complete remission while off OCS for ≥2 months at Week 36.
Time frame: At Week 36
Percentage of Participants Who Remained Relapse-Free up to Week 36
Relapse was defined as the appearance of 3 or more new lesions per month (blisters, eczematous lesions, or urticarial plaques); or at least 1 large (\>10 centimeter \[cm\] diameter) eczematous lesion or urticarial plaques that did not heal within 1 week; or the extension of established lesions or daily pruritus in participants who had achieved disease control.
Time frame: Up to Week 36
Cumulative OCS Exposure From Baseline to Week 36
The cumulative OCS exposure was estimated as the sum over the relevant 4-week periods from the mixed-effect model for repeated measures (MMRM) model. Baseline was defined as the last recorded value on or prior to the date of randomization. Equivalents were prednisone equivalents (converted from mg).
Time frame: Baseline (Day 1) and Week 36
Change From Baseline in Bullous Pemphigoid Disease Area Index (BPDAI) Activity Score at Week 36
BPDAI is a clinician completed tool that is used for independent disease severity assessment to measure disease extent in BP. The total BPDAI activity score is calculated as the arithmetic sum of the 3 subcomponents - cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. The BPDAI total activity gives an indication of disease activity, with score range from 0 (no disease activity) to 360 (severe disease activity). Higher scores indicating greater disease activity. Baseline was defined as the last recorded value on or prior to the date of randomization.
Time frame: Baseline (Day 1) and Week 36
Change From Baseline in BPDAI-Pruritus Score at Week 36
The BPDAI-Pruritus is a separate component of the BPDAI that asks the participant to grade the severity of pruritus over the past 24 hours, the past week, and the past month. For each recall period, severity of pruritus is rated on a numeric rating scale (NRS) ranging from 0 for no itch to 10 for maximal itching. The BPDAI-Pruritus score was computed as the sum of 3 components ranging from 0 to 30. Higher scores indicated worse condition. Baseline was defined as the last recorded value on or prior to the date of randomization.
Time frame: Baseline (Day 1) and Week 36
Cumulative OCS Exposure From Baseline to Week 16
The cumulative OCS exposure was estimated as the sum over the relevant 4-week periods from the MMRM model. Baseline was defined as the last recorded value on or prior to the date of randomization. Equivalents were prednisone equivalents (converted from mg).
Time frame: Baseline (Day 1) and Week 16
This study was conducted in adult participants with symptomatic bullous pemphigoid (BP) at 32 sites in 11 countries. Study consisted of screening period, double-blind (DB) period in which 67 participants were randomized in 1:1 ratio to either receive benralizumab or placebo for 36 weeks followed by optional open-label extension (OLE) period (for participants who completed the DB period), in which all participants received benralizumab for at least 1 year.
| Milestone | DB Period: Benralizumab | DB Period: Placebo | OLE Period: Benralizumab (DB)/Benralizumab (OLE) | OLE Period: Placebo (DB)/Benralizumab (OLE)- |
|---|---|---|---|---|
| Started | 34 | 33 | 0 | 0 |
| Completed | 16 | 19 | 0 | 0 |
| Not completed | 18 | 14 | 0 | 0 |
| Withdrew: Death | 1 | 1 | 0 | 0 |
| Withdrew: Adverse event | 2 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 8 | 6 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 4 | 0 | 0 |
| Withdrew: Physician decision | 4 | 3 | 0 | 0 |
| Withdrew: Other | 1 | 0 | 0 | 0 |
| Milestone | DB Period: Benralizumab | DB Period: Placebo | OLE Period: Benralizumab (DB)/Benralizumab (OLE) | OLE Period: Placebo (DB)/Benralizumab (OLE)- |
|---|---|---|---|---|
| Started | 0 | 0 | 16 | 18 |
| Randomized but did not receive treatment in ole period | 0 | 0 | 0 | 1 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 16 | 18 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 |
| Withdrew: Investigator decision | 0 | 0 | 2 | 1 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 14 | 15 |
| Withdrew: Other | 0 | 0 | 0 | 1 |
A responder was defined as a participant who was in complete remission while off OCS for ≥2 months at Week 36.
| Percentage of participants | DB Period: Benralizumab | DB Period: Placebo |
|---|---|---|
| Percentage of Responders at Week 36 | 11.1 (-2.70 to 26.11) | 5.26 (-5.06 to 15.07) |
Relapse was defined as the appearance of 3 or more new lesions per month (blisters, eczematous lesions, or urticarial plaques); or at least 1 large (\>10 centimeter \[cm\] diameter) eczematous lesion or urticarial plaques that did not heal within 1 week; or the extension of established lesions or daily pruritus in participants who had achieved disease control.
| Percentage of participants | DB Period: Benralizumab | DB Period: Placebo |
|---|---|---|
| Percentage of Participants Who Remained Relapse-Free up to Week 36 | 23.78 (5.95 to 41.61) | 19.79 (1.43 to 38.15) |
The cumulative OCS exposure was estimated as the sum over the relevant 4-week periods from the mixed-effect model for repeated measures (MMRM) model. Baseline was defined as the last recorded value on or prior to the date of randomization. Equivalents were prednisone equivalents (converted from mg).
| mg per kilogram (mg/kg) | DB Period: Benralizumab | DB Period: Placebo |
|---|---|---|
| Cumulative OCS Exposure From Baseline to Week 36 | 71.37 ± 63.19 | 62.71 ± 46.90 |
BPDAI is a clinician completed tool that is used for independent disease severity assessment to measure disease extent in BP. The total BPDAI activity score is calculated as the arithmetic sum of the 3 subcomponents - cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. The BPDAI total activity gives an indication of disease activity, with score range from 0 (no disease activity) to 360 (severe disease activity). Higher scores indicating greater disease activity. Baseline was defined as the last recorded value on or prior to the date of randomization.
| Score on a scale | DB Period: Benralizumab | DB Period: Placebo |
|---|---|---|
| Change From Baseline in Bullous Pemphigoid Disease Area Index (BPDAI) Activity Score at Week 36 | -53.29 ± 46.33 | -52.75 ± 17.36 |
The BPDAI-Pruritus is a separate component of the BPDAI that asks the participant to grade the severity of pruritus over the past 24 hours, the past week, and the past month. For each recall period, severity of pruritus is rated on a numeric rating scale (NRS) ranging from 0 for no itch to 10 for maximal itching. The BPDAI-Pruritus score was computed as the sum of 3 components ranging from 0 to 30. Higher scores indicated worse condition. Baseline was defined as the last recorded value on or prior to the date of randomization.
| Score on a scale | DB Period: Benralizumab | DB Period: Placebo |
|---|---|---|
| Change From Baseline in BPDAI-Pruritus Score at Week 36 | -5.57 ± 7.23 | -16.58 ± 9.21 |
The cumulative OCS exposure was estimated as the sum over the relevant 4-week periods from the MMRM model. Baseline was defined as the last recorded value on or prior to the date of randomization. Equivalents were prednisone equivalents (converted from mg).
| mg/kg | DB Period: Benralizumab | DB Period: Placebo |
|---|---|---|
| Cumulative OCS Exposure From Baseline to Week 16 | 46.90 ± 27.19 | 42.15 ± 33.33 |
Collected over All-cause mortality, serious adverse events (SAEs) and non-serious AEs were collected from first dose of study treatment (Day 1) up to study termination (approximately 133 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DB Period: Benralizumab | 1/34 (2.9%) | 9/34 (26.5%) | 22/34 (64.7%) |
| DB Period: Placebo | 1/33 (3%) | 8/33 (24.2%) | 23/33 (69.7%) |
| OLE Period: Benralizumab (DB)/Benralizumab (OLE) | 0/16 (0%) | 4/16 (25%) | 8/16 (50%) |
| OLE Period: Placebo (DB)/Benralizumab (OLE) | 0/18 (0%) | 2/18 (11.1%) | 8/18 (44.4%) |
| Event | DB Period: Benralizumab | DB Period: Placebo | OLE Period: Benralizumab (DB)/Benralizumab (OLE) | OLE Period: Placebo (DB)/Benralizumab (OLE) |
|---|---|---|---|---|
| Covid-19Infections and infestations | 0/34 | 0/33 | 2/16 | 0/18 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/34 | 0/33 | 2/16 | 0/18 |
| PemphigoidSkin and subcutaneous tissue disorders | 4/34 | 1/33 | 0/16 | 0/18 |
| SepsisInfections and infestations | 0/34 | 1/33 | 0/16 | 1/18 |
| HypotensionVascular disorders | 0/34 | 0/33 | 0/16 | 1/18 |
| CellulitisInfections and infestations | 0/34 | 1/33 | 0/16 | 0/18 |
| Pneumocystis jirovecii pneumoniaInfections and infestations | 0/34 | 1/33 | 0/16 | 0/18 |
| Pneumonia aspirationInfections and infestations | 0/34 | 1/33 | 0/16 | 0/18 |
| Staphylococcal sepsisInfections and infestations | 0/34 | 1/33 | 0/16 | 0/18 |
| FallInjury, poisoning and procedural complications | 0/34 | 1/33 | 0/16 | 0/18 |
| Event | DB Period: Benralizumab | DB Period: Placebo | OLE Period: Benralizumab (DB)/Benralizumab (OLE) | OLE Period: Placebo (DB)/Benralizumab (OLE) |
|---|---|---|---|---|
| Covid-19Infections and infestations | 6/34 | 4/33 | 0/16 | 1/18 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/34 | 2/33 | 2/16 | 2/18 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/34 | 0/33 | 2/16 | 0/18 |
| Oedema peripheralGeneral disorders | 4/34 | 2/33 | 0/16 | 0/18 |
| Herpes zosterInfections and infestations | 4/34 | 2/33 | 0/16 | 0/18 |
| ContusionInjury, poisoning and procedural complications | 0/34 | 3/33 | 0/16 | 0/18 |
| HypertensionVascular disorders | 3/34 | 2/33 | 1/16 | 1/18 |
| Hiatus herniaGastrointestinal disorders | 0/34 | 0/33 | 1/16 | 0/18 |
| Body tineaInfections and infestations | 0/34 | 0/33 | 1/16 | 0/18 |
| NasopharyngitisInfections and infestations | 2/34 | 0/33 | 1/16 | 1/18 |
Full analysis set (FAS) included all randomized participants who received at least 1 dose of investigational product (IP), irrespective of their protocol adherence and continued participation in the study.
| Age, Continuous(Years) | DB Period: Benralizumab | DB Period: Placebo | Total |
|---|---|---|---|
| Mean | 68.0 ± 10.4 | 72.5 ± 11.4 | 70.2 ± 11.1 |
| Sex: Female, Male(Participants) | DB Period: Benralizumab | DB Period: Placebo | Total |
|---|---|---|---|
| Female | 20 | 22 | 42 |
| Male | 14 | 11 | 25 |
| Ethnicity (NIH/OMB)(Participants) | DB Period: Benralizumab | DB Period: Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 |
| Not Hispanic or Latino | 34 | 32 | 66 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | DB Period: Benralizumab | DB Period: Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 14 | 13 | 27 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 2 |
| White | 16 | 20 | 36 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Mar 2021 to primary completion in Oct 2023, 30 months.
Results were first posted in Nov 2024, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Benralizumab